AU2001229441A1 - Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease - Google Patents

Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease

Info

Publication number
AU2001229441A1
AU2001229441A1 AU2001229441A AU2944101A AU2001229441A1 AU 2001229441 A1 AU2001229441 A1 AU 2001229441A1 AU 2001229441 A AU2001229441 A AU 2001229441A AU 2944101 A AU2944101 A AU 2944101A AU 2001229441 A1 AU2001229441 A1 AU 2001229441A1
Authority
AU
Australia
Prior art keywords
pai
asthma
antagonists
treatment
pulmonary disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001229441A
Inventor
Seong H. Cho
Sossiena Demissie-Sanders (Nmi)
Chad K. Oh
Sunny W. Tan
David W Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of AU2001229441A1 publication Critical patent/AU2001229441A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
AU2001229441A 2000-01-14 2001-01-12 Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease Abandoned AU2001229441A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17621100P 2000-01-14 2000-01-14
US60176211 2000-01-14
PCT/US2001/001158 WO2001051085A1 (en) 2000-01-14 2001-01-12 Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
AU2001229441A1 true AU2001229441A1 (en) 2001-07-24

Family

ID=22643429

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001229441A Abandoned AU2001229441A1 (en) 2000-01-14 2001-01-12 Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease

Country Status (3)

Country Link
US (1) US6767540B2 (en)
AU (1) AU2001229441A1 (en)
WO (1) WO2001051085A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500019B1 (en) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm USE IN VITRO OF THE TRANSCRIPTION FACTOR NAK-1 OR NAK-1 REGULATED GENES FOR THE DIAGNOSIS OF INFLAMMATORY AND MALIGNIC DISEASES
US20030199463A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu DNA enzyme to inhibit plasminogen activator inhibitor-1
WO2004061078A2 (en) * 2002-12-31 2004-07-22 Boehringer Ingelheim Pharmaceuticals, Inc. Method to identify and analyze genes having modified expression in activated cells with secretory lysosomes
JP2006520199A (en) * 2003-03-19 2006-09-07 ザ ユニバーシティ オブ ブリティッシュ コロンビア Plasminogen activator inhibitor-1 (PAI-1) haplotype useful as an indicator of patient outcome
AU2004275649A1 (en) * 2003-09-30 2005-04-07 Snow Brand Milk Products Co., Ltd. Agent for promoting osteogenesis and/or inhibiting bone resorption
SI2134374T1 (en) * 2007-03-14 2014-03-31 Bionsil S.R.L. In Liquidazione Btk inhibitors for use in treating chemotherapeutic drug-resistant epithelial tumours
US7771720B2 (en) * 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
EP2566514A4 (en) * 2010-05-03 2013-11-27 Abbvie Inc Methods of inhibiting fibrosis using anti-pai-1 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3742997A1 (en) * 1987-12-18 1989-06-29 Behringwerke Ag PEPTIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE FOR THE OBTAINING OF ANTIBODIES, AND THEIR USE FOR BLOCKING THE PAI-1 ACTIVITY OF HUMAN BLOOD
WO1995030438A2 (en) * 1994-05-10 1995-11-16 Hamilton Civic Hospitals Research Development, Inc. Methods and compositions to enhance endogenous fibrinolytic activity
DE19742717A1 (en) * 1997-09-26 1999-04-01 Knoll Ag Synergistic combination of endothelin antagonist and renin-angiotensin system inhibitor

Also Published As

Publication number Publication date
US20020086838A1 (en) 2002-07-04
WO2001051085A1 (en) 2001-07-19
US6767540B2 (en) 2004-07-27

Similar Documents

Publication Publication Date Title
HUS1700013I1 (en) Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof
MY127812A (en) New use for budesonide and formoterol
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
IL157142A0 (en) Modified antibodies and methods of use
ZA200402858B (en) Novel beta-phenyl-alpha-oxysubstituted propionic derivatives; process for its preparation and their use in the preparation of pharmaceutically important compounds.
HUP0302719A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
AU2002343094A1 (en) Use of ppar activators for the treatment of pulmonary fibrosis
IL145481A0 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders
EP1478748A4 (en) Fce fusion proteins for treatment of allergy and asthma
IL165291A0 (en) Dihydrate dehydroepiandorosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
AU6083899A (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AU2001229441A1 (en) Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
EP1448185A4 (en) Treating asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties
AU2001293891A1 (en) New combination for the treatment of asthma
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
HU0102388D0 (en) Diazepinoindoles for the treatment of chronic obstructive pulmonary disease
PL369737A1 (en) Derivatives of phenoxy-n-'4-(isothiazolidin-1,1-dioxid-2yl)phenyl-valerian- acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors
EP1364031A4 (en) Hiv-like particles and the use thereof
AU2002219473A1 (en) Treatment of asthma and other lung conditions
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
IL136663A0 (en) Use of substituted amino compounds in the treatment of chronic obstructive pulmonary disease
AU2002222169A1 (en) Proteins, genes and their use for diagnosis and treatment of chronic asthma
GB0127010D0 (en) Valve joint and the process of its manufacture
AU2002307114A1 (en) Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders